$RLMD

RELMADA THERAPEUTICS, INC.

Relmada Therapeutics is a publicly traded, clinical-stage biotechnology company developing drug candidates for cancer, neurological disorders and other diseases. Its lead candidate, NDV-01, is a controlled-release intravesical formulation of gemcitabine and docetaxel for non-muscle-invasive bladder cancer. It is in a Phase 2 clinical trial and is being developed for high-risk, BCG-unresponsive and intermediate-risk disease. Relmada’s second candidate, sepranolone, is a neurosteroid being developed for Prader-Willi syndrome, Tourette Syndrome, essential tremor and other conditions related to excessive GABAergic activity. Relmada acquires and licenses development candidates, then advances them through clinical development; it has no approved products or commercial products. Its development programs include NDV-01, licensed from Trigone Pharma, and sepranolone, acquired from Asarina Pharma. The company is headquartered in Coral Gables, Florida.

1
0
0

No SEC Form 4 filings for $RLMD in the last 30 days.

See all $RLMD insider activity →
Low

Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer Former ADSTILADRIN® global clinical development leader brings extensive uro-oncology expertise as Relmada prepares to initiate the Phase 3 SPECTRUM program

Relmada (RLMD) Q3 2026 Earnings Call Transcript

Relmada (RLMD) reported Q3 2026 progress, including IND submissions for NDV-01 and sepranolone by year-end. NDV-01 showed 86% 18-month CR rate in NMIBC, with favorable safety. Phase 3 trials planned. Cash position of $202.1M expected to fund operations through 2029. Net loss was $13.9M, up from $10.1M YoY.

Relmada Therapeutics GAAP EPS of -$0.12 beats by $0.02

Relmada Therapeutics reported Q3 GAAP EPS of -$0.12, exceeding estimates by $0.02. The company's cash and investments rose to $202.1M as of September 30, 2026, up from $93.0M at the end of 2025, according to its press release.

RLMD sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning RLMD (RELMADA THERAPEUTICS, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent RLMD coverage spans earnings, financial news and insider activity.

What's driving RLMD

AlphAI scores every news story that mentions RLMD with an AI model for sentiment and relevance, and aggregates insider trades from RELMADA THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $RLMD

Score
$RLMDLowExec change· appointed

Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer Former ADSTILADRIN® global clinical development leader brings extensive uro-oncology expertise as Relmada prepares to initiate the Phase 3 SPECTRUM program

Relmada (RLMD) Q3 2026 Earnings Call Transcript

Relmada (RLMD) reported Q3 2026 progress, including IND submissions for NDV-01 and sepranolone by year-end. NDV-01 showed 86% 18-month CR rate in NMIBC, with favorable safety. Phase 3 trials planned. Cash position of $202.1M expected to fund operations through 2029. Net loss was $13.9M, up from $10.1M YoY.

$RLMDHighEarnings

Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update ● NDV-01 CMC program on track to submit the IND by year-end 2026, with initiation of the registrational Phase 3 SPECTRUM program upon IND clearance ● Long-term extension ND

Top insider buys and sells disclosed on Friday

Relmada Therapeutics (RLMD) executives bought shares at $4.10-$4.25. PVH (PVH) CEO bought $1M in stock. Clipper Realty (CLPR) director bought $388K in shares. Gloo (GLOO) chair bought 50,000 shares. Hagerty (HGTY) sold $122M in shares. Dell (DELL) saw $55M in sales by Silver Lake. Hinge Health (HNGE) CEO sold $22.3M in shares.

RLMD Jumps As Relmada Insider Buying Sparks Bullish Focus

Relmada Therapeutics Inc. (RLMD) stock rose 12.28% following positive clinical trial news and insider buying by CEO and CFO. The company has no revenue but a strong balance sheet with $218M in cash and no debt. Analysts note a nascent uptrend with support at $4.10 and resistance at $5.00-$5.25. The stock is up from $4.09 to $4.57 on strong volume.

Relmada (RLMD) Q2 2026 Earnings Call Transcript

Relmada Therapeutics (RLMD) reported Q2 2026 results and an execution update. Cash was $217.7M at June 30, 2026, funding operations through 2029. Net loss was $12.9M ($0.11/share). Management expects IND filings for NDV-01 and sepranolone by end-2026 and Phase 3 RESCUE enrollment to start after IND clearance.

$RLMDMedEarnings

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update ● Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational

Related tickers